Gemcitabin

DRUG6 trials

Sponsors

Spanish Lung Cancer Group, Beijing Tongren Hospital, German Cancer Research Center, Peking University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Advanced Stage or Metastatic Pancreatic Ductal AdenocarcinomaBCG-Unresponsive Bladder CancerBiliary Tract Cancer (BTC)CYP3A InhibitorExtranodal NK/T-cell Lymphoma, Nasal TypeNon-Muscle-Invasive Bladder CancerNon-Small Cell Lung CancerPancreatic Adenocarcinoma

Phase 1

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

TerminatedNCT05494866

German Cancer Research CenterAdvanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, CYP3A Inhibitor, Pancreatic Adenocarcinoma +2

Start: 2022-12-07End: 2024-03-15Updated: 2025-03-25

Phase 2

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Beijing Tongren HospitalExtranodal NK/T-cell Lymphoma, Nasal Type

Start: 2020-03-21End: 2023-04-30Target: 29Updated: 2020-05-28

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Active, not recruitingNCT07480850

Cancer Institute and Hospital, Chinese Academy of Medical SciencesRefractory Diffuse Large B-Cell Lymphoma (DLBCL)

Start: 2026-01-01End: 2028-01-02Target: 40Updated: 2026-03-18

Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

RecruitingNCT07747740

Blokhin's Russian Cancer Research CenterBCG-Unresponsive Bladder Cancer, Non-Muscle-Invasive Bladder Cancer

Start: 2026-07-09End: 2030-12-30Target: 228Updated: 2026-08-05

Phase 3

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

CompletedNCT00446225

Spanish Lung Cancer GroupNon-Small Cell Lung Cancer

Start: 2007-02-15End: 2012-12-31Updated: 2025-03-05

Unknown Phase

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

RecruitingNCT07466238

Peking UniversityBiliary Tract Cancer (BTC)

Start: 2026-03-31End: 2029-03-31Target: 40Updated: 2026-05-08

Related Papers

Abstract CT186: Pulmonary toxicity associated with increased 6-OH-paclitaxel exposure in pancreatic cancer patients treated with nab-paclitaxel, gemcitabine and cobicistat: Results of the IntenSify trial

Cancer Research2026-04-17

Protocol of the <scp>IntenSify‐Trial</scp>: An open‐label phase I trial of the <scp>CYP3A</scp> inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

Clinical and Translational Science2023-11-035 citations

AB036. Comparison of the effectiveness of gefitinib, erlotinib and afatinib in epidermal growth factor receptor mutated tumors of non-small cell lung cancer

Annals of Translational Medicine2016-11-01

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

JAMA Oncology2015-02-26234 citations

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

2014-06-0126 citations

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.

2014-02-03193 citations

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

2012-01-264247 citations